Changes in Medical Management of Inflammatory Bowel Disease and Reducing Surgical Risk: Investigating Causality Through the Bradford-Hill Criteria
Abstract
:1. Introduction
2. Relevant Sections
2.1. Criterion No. 1—Temporal Sequence: Does an Increase in Anti-TNFα Prescription Truly Precede the Reduction in Surgical Risk?
2.2. Criterion No. 2—Strength of Association: Is the Relative Risk Reduction or Odds Ratio Statistically Significant?
2.3. Criterion No. 3—Consistency of Association: Has the Association Been Found in Multiple Studies?
2.4. Criterion No. 4—Biological Gradient: Is There a Dose–Response Relationship?
2.5. Criterion No. 5—Specificity of Association: Does Exposure Lead to a Single Outcome?
2.6. Criteria No. 6 and 7—Biological Plausibility and Consistency with Current Knowledge—Does the Association Make Sense in Light of Our Knowledge?
2.7. Criterion No. 8—Is There Experimental Evidence to Support?
2.8. Criterion No. 9—Analogy Criterion: Is the Association Similar to Others?
3. Discussion
4. Conclusions
Funding
Conflicts of Interest
References
- Peyrin-Biroulet, L.; Sandborn, W. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am. J. Gastroenterol. 2015, 110, 1324–1338. [Google Scholar] [CrossRef] [PubMed]
- Turner, D.; Ricciuto, A. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target Strategies in IBD. Gastroenterology 2021, 160, 1570–1583. [Google Scholar] [CrossRef]
- Le Berre, C.; Peyrin-Biroulet, L. Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: The SPIRIT Consensus From the IOIBD. Gastroenterology 2021, 160, 1452–1460.e21. [Google Scholar] [CrossRef] [PubMed]
- Bischoff, S.C.; Bager, P.; Escher, J.; Forbes, A.; Hébuterne, X.; Hvas, C.L.; Joly, F.; Klek, S.; Krznaric, Z.; Ockenga, J.; et al. ESPEN Guideline on Clinical Nutrition in Inflammatory Bowel Disease. Clin. Nutr. 2023, 42, 352–379. [Google Scholar] [CrossRef]
- Rungoe, C.; Langholz, E.; Andersson, M.; Basit, S.; Nielsen, N.M.; Wohlfahrt, J.; Jess, T. Changes in Medical Treatment and Surgery Rates in Inflammatory Bowel Disease: A Nationwide Cohort Study 1979–2011. Gut 2014, 63, 1607–1616. [Google Scholar] [CrossRef]
- Jeuring, S.F.G.; Bours, P.H.A.; Zeegers, M.P.; Ambergen, T.W.; Heuvel, T.R.v.D.; Romberg-Camps, M.J.L.; van Bodegraven, A.A.; Oostenbrug, L.E.; Breukink, S.O.; Stassen, L.P.S.; et al. Disease Outcome of Ulcerative Colitis in an Era of Changing Treatment Strategies: Results from the Dutch Population-Based IBDSL Cohort. J. Crohn’s Colitis 2015, 9, 837–845. [Google Scholar] [CrossRef]
- Jeuring, S.F.G.; Heuvel, T.R.A.v.D.; Liu, L.Y.L.; Zeegers, M.P.; Hameeteman, W.H.; Romberg-Camps, M.J.L.; E Oostenbrug, L.; Masclee, A.A.M.; Jonkers, D.M.A.E.; Pierik, M.J. Improvements in the Long-Term Outcome of Crohn’s Disease Over the Past Two Decades and the Relation to Changes in Medical Management: Results from the Population-Based IBDSL Cohort. Am. J. Gastroenterol. 2017, 112, 325–336. [Google Scholar] [CrossRef]
- Burr, N.E.; Lord, R.; Hull, M.A.; Subramanian, V. Decreasing Risk of First and Subsequent Surgeries in Patients with Crohn’s Disease in England from 1994 through 2013. Clin. Gastroenterol. Hepatol. 2019, 17, 2042–2049.e4. [Google Scholar] [CrossRef]
- Kalman, T.D.; Everhov, Å.H.; Nordenvall, C.; Sachs, M.C.; Halfvarson, J.; Ekbom, A.; Ludvigsson, J.F.; Myrelid, P.; Olén, O. Decrease in Primary but Not in Secondary Abdominal Surgery for Crohn’s Disease: Nationwide Cohort Study, 1990–2014. Br. J. Surg. 2020, 107, 1529–1538. [Google Scholar] [CrossRef]
- Ley, D.; Leroyer, A.; Dupont, C.; Sarter, H.; Bertrand, V.; Spyckerelle, C.; Guillon, N.; Wils, P.; Savoye, G.; Turck, D.; et al. New Therapeutic Strategies Have Changed the Natural History of Pediatric Crohn’s Disease: A Two-Decade Population-Based Study. Clin. Gastroenterol. Hepatol. 2022, 20, 2588–2597.e1. [Google Scholar] [CrossRef]
- Ramadas, A.V.; Gunesh, S.; Thomas, G.A.; Williams, G.T.; Hawthorne, A.B. Natural History of Crohn’s Disease in a Population-Based Cohort from Cardiff (1986–2003): A Study of Changes in Medical Treatment and Surgical Resection Rates. Gut 2010, 59, 1200–1206. [Google Scholar] [CrossRef] [PubMed]
- Nguyen, G.C.; Nugent, Z.; Shaw, S.; Bernstein, C.N. Outcomes of Patients with Crohn’s Disease Improved from 1988 to 2008 and Were Associated with Increased Specialist Care. Gastroenterology 2011, 141, 90–97. [Google Scholar] [CrossRef] [PubMed]
- Gonczi, L.; Lakatos, L.; Golovics, P.A.; Ilias, A.; Pandur, T.; David, G.; Erdelyi, Z.; Szita, I.; Al Khoury, A.; Lakatos, P.L. Declining Trends of Reoperations and Disease Behaviour Progression in Crohn’s Disease over Different Therapeutic Eras—A Prospective, Population-Based Study from Western Hungary between 1977–2020, Data from the Veszprem Cohort. J. Crohn’s Colitis 2023, 17, 1980–1987. [Google Scholar] [CrossRef]
- Jabbari, M.; Salari-Moghaddam, A.; Bagheri, A.; Larijani, B.; Esmaillzadeh, A. A Systematic Review and Dose-Response Meta-Analysis of Prospective Cohort Studies on Coffee Consumption and Risk of Lung Cancer. Sci. Rep. 2024, 14, 14991. [Google Scholar] [CrossRef]
- Aratari, A.; Scribano, M.L.; Pugliese, D.; Baccolini, V.; De Biasio, F.; Verna, S.; Morretta, C.; Festa, S.; Armuzzi, A.; Papi, C. Crohn’s Disease after Surgery: Changes in Post-Operative Management Strategies over Time and Their Impact on Long-Term Re-Operation Rate—A Retrospective Multicentre Real-World Study. Aliment. Pharmacol. Ther. 2024, 59, 1579–1588. [Google Scholar] [CrossRef]
- Hill, A.B. The Environment and Disease: Association or Causation? Proc. R. Soc. Med. 1965, 58, 295–300. [Google Scholar] [CrossRef]
- Rothman, K.J.; Greenland, S. Hill’s Criteria for Causality. In Encyclopedia of Biostatistics; Armitage, P., Colton, T., Eds.; John Wiley & Sons, Ltd.: Chichester, UK, 2005. [Google Scholar] [CrossRef]
- King, J. Bradford Hill Criteria for Causal Inference; Julian King & Associates: Auckland, New Zealand, 2015; Available online: www.julianking.co.nz (accessed on 25 May 2025).
- Grimes, D.A.; Schulz, K.F. Bias and Causal Associations in Observational Research. Lancet 2002, 359, 248–252. [Google Scholar] [CrossRef]
- Shimonovich, M.; Pearce, A.; Thomson, H.; Keyes, K.; Katikireddi, S.V. Assessing Causality in Epidemiology: Revisiting Bradford Hill to Incorporate Developments in Causal Thinking. Eur. J. Epidemiol. 2021, 36, 873–887. [Google Scholar] [CrossRef]
- Höfler, M. The Bradford Hill Considerations on Causality: A Counterfactual Perspective. Emerg. Themes Epidemiol. 2005, 2, 11. [Google Scholar] [CrossRef]
- Fedak, K.M.; Bernal, A.; Capshaw, Z.A.; Gross, S. Applying the Bradford Hill Criteria in the 21st Century: How Data Integration Has Changed Causal Inference in Molecular Epidemiology. Emerg. Themes Epidemiol. 2015, 12, 14. [Google Scholar] [CrossRef]
- Tsai, L.; Ma, C.; Dulai, P.S.; Prokop, L.J.; Eisenstein, S.; Ramamoorthy, S.L.; Feagan, B.G.; Jairath, V.; Sandborn, W.J.; Singh, S. Contemporary Risk of Surgery in Patients With Ulcerative Colitis and Crohn’s Disease: A Meta-Analysis of Population-Based Cohorts. Clin. Gastroenterol. Hepatol. 2021, 19, 2031–2045.e11. [Google Scholar] [CrossRef] [PubMed]
- Frolkis, A.D.; Dykeman, J.; Negrón, M.E.; Debruyn, J.; Jette, N.; Fiest, K.M.; Frolkis, T.; Barkema, H.W.; Rioux, K.P.; Panaccione, R.; et al. Risk of Surgery for Inflammatory Bowel Diseases Has Decreased Over Time: A Systematic Review and Meta-Analysis of Population-Based Studies. Gastroenterology 2013, 145, 996–1006. [Google Scholar] [CrossRef] [PubMed]
- Qvist, N.; Vadstrup, K.; Alulis, S.; Borsi, A.; Munkholm, P.; Olsen, J. Increased Use of Biologics in the Era of TNF-α Inhibitors Did Not Reduce Surgical Rate but Prolonged the Time from Diagnosis to First-Time Intestinal Resection Among Patients with Crohn’s Disease and Ulcerative Colitis—A Danish Register-Based Study from 2003–2016. Scand. J. Gastroenterol. 2021, 56, 537–544. [Google Scholar] [CrossRef]
- Murthy, S.K.; Begum, J.; Benchimol, E.I.; Bernstein, C.N.; Kaplan, G.G.; McCurdy, J.D.; Singh, H.; Targownik, L.; Taljaard, M. Introduction of Anti-TNF Therapy Has Not Yielded Expected Declines in Hospitalisation and Intestinal Resection Rates in Inflammatory Bowel Diseases: A Population-Based Interrupted Time Series Study. Gut 2020, 69, 274–282. [Google Scholar] [CrossRef]
- Osei, J.A.; Peña-Sánchez, J.N.; Fowler, S.A.; Muhajarine, N.; Kaplan, G.G.; Lix, L.M. Population-Based Evidence from a Western Canadian Province of the Decreasing Incidence Rates and Trends of Inflammatory Bowel Disease Among Adults. J. Can. Assoc. Gastroenterol. 2020, 4, 186–193. [Google Scholar] [CrossRef]
- Sackett, D.L.; Haynes, R.B.; Guyatt, G.H.; Tugwell, P. Clinical Epidemiology: A Basic Science for Clinical Medicine, 2nd ed.; Little, Brown and Company: Boston, MA, USA, 1991. [Google Scholar]
- Law, C.C.Y.; Tkachuk, B.; Lieto, S.; Narula, N.; Walsh, S.; Colombel, J.-F.; Ungaro, R.C. Early Biologic Treatment Decreases Risk of Surgery in Crohn’s Disease but Not in Ulcerative Colitis: Systematic Review and Meta-Analysis. Inflamm. Bowel Dis. 2023, 30, 1080–1086. [Google Scholar] [CrossRef]
- Burisch, J.; Kiudelis, G.; Kupcinskas, L.; Kievit, H.A.L.; Andersen, K.W.; Andersen, V.; Salupere, R.; Pedersen, N.; Kjeldsen, J.; D’incà, R.; et al. Natural Disease Course of Crohn’s Disease During the First 5 Years After Diagnosis in a European Population-Based Inception Cohort: An Epi-IBD Study. Gut 2019, 68, 423–433. [Google Scholar] [CrossRef]
- Zhao, M.; Jensen, M.S.; Knudsen, T.; Kelsen, J.; Coskun, M.; Kjellberg, J.; Burisch, J. Trends in the Use of Biologicals and Their Treatment Outcomes Among Patients with Inflammatory Bowel Diseases—A Danish Nationwide Cohort Study. Aliment. Pharmacol. Ther. 2022, 55, 541–557. [Google Scholar] [CrossRef]
- Peyrin-Biroulet, L.; Oussalah, A.; Williet, N.; Pillot, C.; Bresler, L.; Bigard, M.A. Impact of Azathioprine and Tumour Necrosis Factor Antagonists on the Need for Surgery in Newly Diagnosed Crohn’s Disease. Gut 2011, 60, 930–936. [Google Scholar] [CrossRef]
- Eberhardson, M.; Söderling, J.K.; Neovius, M.; Cars, T.; Myrelid, P.; Ludvigsson, J.F.; Askling, J.; Ekbom, A.; Olén, O. Anti-TNF Treatment in Crohn’s Disease and Risk of Bowel Resection—A Population-Based Cohort Study. Aliment. Pharmacol. Ther. 2017, 46, 589–598. [Google Scholar] [CrossRef]
- To, N.; Ford, A.C.; Gracie, D.J. Systematic Review with Meta-Analysis: The Effect of Tobacco Smoking on the Natural History of Ulcerative Colitis. Aliment. Pharmacol. Ther. 2016, 44, 117–126. [Google Scholar] [CrossRef] [PubMed]
- Peyrin-Biroulet, L.; Ferrante, M.; Magro, F.; Campbell, S.; Franchimont, D.; Fidder, H.; Strid, H.; Ardizzone, S.; Veereman-Wauters, G.; Chevaux, J.-B.; et al. Results from the 2nd Scientific Workshop of the ECCO. I: Impact of Mucosal Healing on the Course of Inflammatory Bowel Disease. J. Crohns Colitis 2011, 5, 477–483. [Google Scholar] [CrossRef] [PubMed]
- Cholapranee, A.; Hazlewood, G.S.; Kaplan, G.G.; Peyrin-Biroulet, L.; Ananthakrishnan, A.N. Systematic Review with Meta-Analysis: Comparative Efficacy of Biologics for Induction and Maintenance of Mucosal Healing in Crohn’s Disease and Ulcerative Colitis Controlled Trials. Aliment. Pharmacol. Ther. 2017, 45, 1291–1302. [Google Scholar] [CrossRef]
- Hanauer, S.B.; Feagan, B.G.; Lichtenstein, G.R.; Mayer, L.F.; Schreiber, S.; Colombel, J.F.; Rachmilewitz, D.; Wolf, D.C.; Olson, A.; Bao, W.; et al. Maintenance Infliximab for Crohn’s Disease: The ACCENT I Randomised Trial. Lancet 2002, 359, 1541–1549. [Google Scholar] [CrossRef]
- Sands, B.E.; Blank, M.A.; Patel, K.; van Deventer, S.J.; ACCENT II Study. Long-Term Treatment of Rectovaginal Fistulas in Crohn’s Disease: Response to Infliximab in the ACCENT II Study. Clin. Gastroenterol. Hepatol. 2004, 2, 912–920. [Google Scholar] [CrossRef]
- Colombel, J.; Sandborn, W.J.; Rutgeerts, P.; Enns, R.; Hanauer, S.B.; Panaccione, R.; Schreiber, S.; Byczkowski, D.; Li, J.; Kent, J.D.; et al. Adalimumab for Maintenance of Clinical Response and Remission in Patients with Crohn’s Disease: The CHARM Trial. Gastroenterology 2007, 132, 52–65. [Google Scholar] [CrossRef]
- Rutgeerts, P.; Sandborn, W.J.; Feagan, B.G.; Reinisch, W.; Olson, A.; Johanns, J.; Travers, S.; Rachmilewitz, D.; Hanauer, S.B.; Lichtenstein, G.R.; et al. Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis. N. Engl. J. Med. 2005, 353, 2462–2476. [Google Scholar] [CrossRef]
- Mao, E.J.; Hazlewood, G.S.; Kaplan, G.G.; Peyrin-Biroulet, L.; Ananthakrishnan, A.N. Systematic Review with Meta-Analysis: Comparative Efficacy of Immunosuppressants and Biologics for Reducing Hospitalisation and Surgery in Crohn’s Disease and Ulcerative Colitis. Aliment. Pharmacol. Ther. 2017, 45, 3–13. [Google Scholar] [CrossRef]
- Le Berre, C.; Danese, S.; Peyrin-Biroulet, L. Can We Change the Natural Course of Inflammatory Bowel Disease? Therap. Adv. Gastroenterol. 2023, 16, 17562848231163118. [Google Scholar] [CrossRef]
- Macaluso, F.S.; Caprioli, F.; Benedan, L.; Bezzio, C.; Caporali, R.; Cauli, A.; Chimenti, M.S.; Ciccia, F.; D’Angelo, S.; Fantini, M.C.; et al. The Management of Patients with Inflammatory Bowel Disease-Associated Spondyloarthritis: Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) and Italian Society of Rheumatology (SIR) Recommendations Based on a Pseudo-Delphi Consensus. Autoimmun. Rev. 2024, 23, 103533. [Google Scholar] [CrossRef]
- Sepriano, A.; Ramiro, S.; van der Heijde, D.; Landewé, R. Biological DMARDs and Disease Modification in Axial Spondyloarthritis: A Review through the Lens of Causal Inference. RMD Open 2021, 7, e001654. [Google Scholar] [CrossRef] [PubMed]
- Schoepfer, A.M.; Vavricka, S.; Zahnd-Straumann, N.; Straumann, A.; Beglinger, C. Monitoring Inflammatory Bowel Disease Activity: Clinical Activity Is Judged to Be More Relevant Than Endoscopic Severity or Biomarkers. J. Crohns Colitis 2012, 6, 412–418. [Google Scholar] [CrossRef] [PubMed]
- Limketkai, B.N.; Singh, S.; Jairath, V.; Sandborn, W.J.; Dulai, P.S. US Practice Patterns and Impact of Monitoring for Mucosal Inflammation After Biologic Initiation in Inflammatory Bowel Disease. Inflamm. Bowel Dis. 2019, 25, 1828–1837. [Google Scholar] [CrossRef]
- Siegel, C.A.; Yang, F.; Eslava, S.; Cai, Z. Treatment Pathways Leading to Biologic Therapies for Ulcerative Colitis and Crohn’s Disease in the United States. Clin. Transl. Gastroenterol. 2020, 11, e00128. [Google Scholar] [CrossRef]
- Gu, P.; Clifford, E.; Gilman, A.; Chang, C.; Moss, E.; Fudman, D.I.; Kilgore, P.; Cvek, U.; Trutschl, M.; Alexander, J.S.; et al. Improved Healthcare Access Reduces Requirements for Surgery in Indigent IBD Patients Using Biologic Therapy: A “Safety-Net” Hospital Experience. Pathophysiology 2022, 29, 383–393. [Google Scholar] [CrossRef]
|
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Maggi, D.; Papi, C.; Festa, S.; Aratari, A. Changes in Medical Management of Inflammatory Bowel Disease and Reducing Surgical Risk: Investigating Causality Through the Bradford-Hill Criteria. J. Clin. Med. 2025, 14, 3824. https://doi.org/10.3390/jcm14113824
Maggi D, Papi C, Festa S, Aratari A. Changes in Medical Management of Inflammatory Bowel Disease and Reducing Surgical Risk: Investigating Causality Through the Bradford-Hill Criteria. Journal of Clinical Medicine. 2025; 14(11):3824. https://doi.org/10.3390/jcm14113824
Chicago/Turabian StyleMaggi, Daniela, Claudio Papi, Stefano Festa, and Annalisa Aratari. 2025. "Changes in Medical Management of Inflammatory Bowel Disease and Reducing Surgical Risk: Investigating Causality Through the Bradford-Hill Criteria" Journal of Clinical Medicine 14, no. 11: 3824. https://doi.org/10.3390/jcm14113824
APA StyleMaggi, D., Papi, C., Festa, S., & Aratari, A. (2025). Changes in Medical Management of Inflammatory Bowel Disease and Reducing Surgical Risk: Investigating Causality Through the Bradford-Hill Criteria. Journal of Clinical Medicine, 14(11), 3824. https://doi.org/10.3390/jcm14113824